A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled 15 charts
Flu-Mel-Vel
Phase 2 Completed
54 enrolled 8 charts
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Phase 2 Completed
40 enrolled
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Phase 2 Completed
17 enrolled 11 charts
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
15 enrolled 9 charts
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Phase 2 Completed
43 enrolled 9 charts
CD30 CAR for CD30+ NSGCT
Phase 2 Completed
2 enrolled
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Phase 2 Completed
102 enrolled 12 charts
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
Phase 2 Completed
24 enrolled 9 charts
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Phase 2 Completed
78 enrolled 13 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Phase 2 Completed
40 enrolled 17 charts
ICLL07GAI
Phase 2 Completed
135 enrolled
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Phase 2 Completed
34 enrolled 18 charts
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Phase 2 Completed
80 enrolled 56 charts
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Phase 2 Completed
52 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Phase 2 Completed
84 enrolled
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Phase 2 Completed
18 enrolled 13 charts
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Phase 2 Completed
7 enrolled 12 charts
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Phase 2 Completed
21 enrolled 24 charts
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Phase 2 Completed
20 enrolled 16 charts
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
Phase 2 Completed
11 enrolled 12 charts
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
Phase 2 Completed
41 enrolled 10 charts
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Phase 2 Completed
32 enrolled 16 charts
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
Phase 2 Completed
27 enrolled 13 charts
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Phase 2 Completed
25 enrolled 10 charts
Allo HSCT Using RIC for Hematological Diseases
Phase 2 Completed
156 enrolled
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
Phase 2 Completed
22 enrolled 15 charts
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
Phase 2 Completed
201 enrolled 12 charts
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Completed
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Phase 2 Completed
418 enrolled 15 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
68 enrolled 8 charts
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Phase 2 Completed
25 enrolled 10 charts
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Completed
66 enrolled 12 charts
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Phase 2 Completed
130 enrolled 21 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Completed
33 enrolled 21 charts
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Phase 2 Completed
57 enrolled 22 charts
BMT CTN 0903
Phase 2 Completed
20 enrolled 25 charts
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Phase 2 Completed
11 enrolled 12 charts
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Phase 2 Completed
117 enrolled 27 charts
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase 2 Completed
82 enrolled 18 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase 2 Completed
49 enrolled 21 charts
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Phase 2 Completed
30 enrolled 28 charts
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
Phase 2 Completed
40 enrolled 21 charts
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Phase 2 Completed
62 enrolled 15 charts